# Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension

> **NCT00872586** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 304 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** olmesartan medoxomil + hydrochlorothiazide
- **DRUG:** olmesartan medoxomil

## Key facts

- **NCT ID:** NCT00872586
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2007-07
- **Final completion:** 2007-08
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2010-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00872586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00872586, "Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00872586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*